Display options
Cite
Wenner DM, Kimmelman J, London AJ. Patient-Funded Trials: Opportunity or Liability?. Cell Stem Cell. 2015;17(2):135-7doi: 10.1016/j.stem.2015.07.016.
Wenner, D. M., Kimmelman, J., & London, A. J. (2015). Patient-Funded Trials: Opportunity or Liability?. Cell stem cell, 17(2), 135-7. https://doi.org/10.1016/j.stem.2015.07.016
Wenner, Danielle Marie, et al. "Patient-Funded Trials: Opportunity or Liability?." Cell stem cell vol. 17,2 (2015): 135-7. doi: https://doi.org/10.1016/j.stem.2015.07.016
Wenner DM, Kimmelman J, London AJ. Patient-Funded Trials: Opportunity or Liability?. Cell Stem Cell. 2015 Aug 06;17(2):135-7. doi: 10.1016/j.stem.2015.07.016. PMID: 26253199.
Copy Download .nbib Format: NLM
Share it on

Cell Stem Cell. 2015 Aug 06;17(2):135-7. doi: 10.1016/j.stem.2015.07.016.

Patient-Funded Trials: Opportunity or Liability?.

Cell stem cell

Danielle Marie Wenner, Jonathan Kimmelman, Alex John London

Affiliations

  1. Department of Philosophy and Center for Ethics and Policy, Carnegie Mellon University, Pittsburgh, PA 15213, USA.
  2. Studies of Translation, Ethics and Medicine (STREAM), Biomedical Ethics Unit, Social Studies of Medicine, McGill University, Montreal, QC H3A 1X1, Canada.
  3. Department of Philosophy and Center for Ethics and Policy, Carnegie Mellon University, Pittsburgh, PA 15213, USA. Electronic address: [email protected].

PMID: 26253199 DOI: 10.1016/j.stem.2015.07.016

Abstract

Patient-funded trials (PFTs) are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols.

Copyright © 2015 Elsevier Inc. All rights reserved.

MeSH terms

Publication Types